Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A; Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology, 2008, vol. 26, issue 35, p 5705, ISSN 15277755. ISBN 15277755.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via Electronic Journal Services